tiprankstipranks

Organovo Announces 1-for-12 Reverse Stock Split

Story Highlights
  • Organovo announced a 1-for-12 reverse stock split effective March 20, 2025.
  • The reverse split aims to regain Nasdaq compliance by reducing outstanding shares to 1.8 million.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
Organovo Announces 1-for-12 Reverse Stock Split

An update from Organovo Holdings ( (ONVO) ) is now available.

On March 19, 2025, Organovo Holdings, Inc. announced a 1-for-12 reverse stock split of its common stock, effective March 20, 2025, to regain compliance with Nasdaq’s minimum bid price requirement. This move will reduce the number of outstanding shares from approximately 21.4 million to 1.8 million, while maintaining the current par value and authorized shares, and adjusting equity incentive plans proportionately.

More about Organovo Holdings

Organovo Holdings, Inc. is a clinical stage biotechnology company that focuses on developing novel treatment approaches for inflammatory bowel disease (IBD). The company utilizes proprietary technology to create three-dimensional (3D) human tissues that replicate key aspects of native human tissue, aiding in drug development.

YTD Price Performance: -8.41%

Average Trading Volume: 8,037,711

Technical Sentiment Consensus Rating: Buy

Current Market Cap: $7.05M

For a thorough assessment of ONVO stock, go to TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App